熱門資訊> 正文
Sensei Biotherapeutics GAAP每股收益为-0.27美元
2025-05-06 23:15
- Sensei Biotherapeutics press release (NASDAQ:SNSE): Q1 GAAP EPS of -$0.27.
- Cash, cash equivalents and marketable securities were $34.3 million as of March 31, 2025, as compared to $41.3 million as of December 31, 2024.
More on Sensei Biotherapeutics
- Seeking Alpha’s Quant Rating on Sensei Biotherapeutics
- Historical earnings data for Sensei Biotherapeutics
- Financial information for Sensei Biotherapeutics
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。